NTRA
Natera, Inc.
Is NTRA Halal?
Genetic diagnostics — prenatal and cancer testing is permissible medical science.
What You Should Know
Natera develops cell-free DNA testing technology used for prenatal screening (Panorama), cancer monitoring (Signatera), and organ transplant rejection detection (Prospera). Its March 31, 2026 Form 10-Q reports $2,614.398 million of assets, $80.305 million of short-term debt financing, $1,087.932 million of cash, $417.595 million of receivables and $696.644 million of quarterly revenue. Debt/assets is 3.07%, but liquidity/assets is 41.61% and receivables-plus-cash/assets is 57.59%; the examined FTSE, MSCI and Malaysia asset-based financial screens therefore fail despite the generally permissible diagnostic business. The filing's mixed interest-and-other-income line is $9.600 million, or 1.38% of revenue, and is not a fixed purification rate.
⚠️ Concerns
- •Not yet profitable — high R&D spending
- •Prenatal testing used for non-medical decisions by some (application concern, not the product)
- •Large cash and receivables balances exceed several asset-based limits
- •Interest-and-other-income line is mixed and not a purification ruling
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
80.305 / 2,614.398
1,087.932 / 2,614.398
1,505.527 / 2,614.398
9.6 / 696.644
- Financial
- Fails
- Overall
- Fails
Debt/assets is 3.07%, but liquidity/assets is 41.61% and receivables-plus-cash/assets is 57.59%, above the examined FTSE limits; the mixed income upper bound is 1.38% of revenue.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 41.61% and receivables-plus-cash/assets is 57.59%, above the examined MSCI total-assets limits; debt/assets remains below its limit.
- Financial
- Fails
- Overall
- Fails
Liquidity/assets is 41.61%, above the examined Malaysia 33% limit; debt/assets is below its limit. This is a calculation against the named ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the liquidity and receivables failures remain independently documented.
Business-activity disclosure
Natera develops and provides molecular and genetic diagnostic testing for women's health, oncology and organ health. The core diagnostic activity is generally permissible.
Limitation: The filing does not allocate every test, licensing contract or downstream patient decision into a scholar-approved prohibited-revenue numerator.
Purification
Natera reports a mixed $9.600 million interest-and-other-income line and does not provide a scholar-approved purification percentage; no fixed rate is invented.
Inputs, assumptions and primary sources
- Amounts are USD millions converted from Natera's March 31, 2026 Form 10-Q values reported in thousands.
- Interest-bearing debt is the $80.305 million short-term debt-financing balance; operating lease liabilities and contingent consideration are excluded.
- Cash, cash equivalents and restricted cash total $1,087.932 million; no separately identified interest-bearing securities balance is added.
- Accounts receivable are $417.595 million net; first-quarter total revenue is $696.644 million.
- The filing reports $9.600 million of interest and other income, net, a mixed line that includes interest, investment remeasurement and other items; it is used only as a conservative upper bound.
- Genetic diagnostics for oncology, women's health and organ health are generally permissible medical services; prenatal application and data-use questions remain qualitative.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →